ATOS Atossa Genetics Inc.

0  -0%
Previous Close 1.51
Open 1.48
Price To Book 0.81
Market Cap 8508789
Shares 5,646,552
Volume 49,794
Short Ratio
Av. Daily Volume 1,149,549

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2018
Breast cancer - patients who are not responding to Tamoxifen
Phase 2 completion of enrollment announced October 12, 2018.
Mammographic breast density (MBD)
Phase 2 trial ongoing - noted December 28, 2017.
Cuctal carcinoma in situ(DCIS) - invasive breast cancer
Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives. Final data January 9, 2019 confirmed objectives met.
Male breast cancer and Gynecomastia
Phase 2 commencement of enrollment announced July 13, 2018.
Breast cancer - window of opportunity setting

Latest News

  1. Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
  2. Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force
  3. Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter
  4. Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019
  5. Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics
  6. 4 Healthcare Stocks Looking To Set January Highs
  7. Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen
  8. Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape
  9. "The Roller Coaster Ride Continues"
  10. Edison issues outlook on Atossa Genetics (ATOS)
  11. Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
  12. ''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter
  13. "...Amidst Market Volatility" Vista Partners' October Macroeconomic & Investment Monthly Newsletter
  14. ''Superfirms' Domination Influences Economic Factors''
  15. An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?"

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19579080
  2. 8-K - Current report 19527229
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181179636
  4. 8-K - Current report 181178042
  5. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181177967
  6. 8-K - Current report 181067994
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181012489
  8. 8-K - Current report 181012467
  9. 8-K - Current report 18934675
  10. EFFECT - Notice of Effectiveness 18900648